Comparative study: CNS progression in response to treatment with gefitinib or erlotinib
In Chinese patients with pre-existing brain metastases, erlotinib treatment significantly prolonged time to neurological progression compared with gefitinib treatment.1
nTTP in pre-existing brain metastases1
Time to neurological progression (nTTP) was significantly longer in erlotinib- versus gefitinib-treated patients with pre-existing brain metastases.
Progression-free survival (all patients)1
Overall, PFS was not significantly different between patients treated with erlotinib compared with those treated with gefitinib.